When was Bio X Cell founded?

Bio X Cell was founded in 1997.

Where is Bio X Cell located?

Bio X Cell is headquartered in Lebanon, United States. It is registered at West Lebanon, New Hampshire.

How many employees does Bio X Cell have?

As of Dec 31, 2022, Bio X Cell has 23 employees, reflecting a 36% year-over-year growth in headcount.

Is Bio X Cell a funded company?

Bio X Cell is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Bio X Cell rank among its competitors?

Bio X Cell ranks 7th amongst 272 active competitors, of which 16 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Y-Biologics, which secured $25.2M in Aug, 2025.

Who are the top competitors of Bio X Cell?

Bio X Cell's top competitors include Sino Biological, GenScript and Y-Biologics. Among them, Y-Biologics secured the most recent funding round in August, 2025.

Bio X Cell - 2026 Company Profile, Team & Competitors

Bio X Cell is an acquired company based in Lebanon (United States), founded in 1997 by Klaus Lubbe. It operates as a Provider of antibodies and antibody production services for in vivo use. The company has 272 active competitors, including 16 funded and 39 that have exited. Its top competitors include companies like Sino Biological, GenScript and Y-Biologics.

Company Details

Provider of antibodies and antibody production services for in vivo use. The company offers antibodies for in vivo studies and functional assays, as well as recombinant antibodies known as RecombiMAb antibodies. It also, offer contract services for antibody production.

Website: bioxcell.com
Social
Email ID: *****@bxcell.com
Phone Number: +1 **********
Registered Address: West Lebanon, New Hampshire

Key Metrics

Founded Year

1997

Location

Lebanon, United States

Stage

Acquired

Ranked

7^th among 272 active competitors

Employee Count

23 as on Dec 31, 2022

Similar Companies

Sino Biological & 329 more

Exit Details

Acquired by Windjammer Capital Investors (Dec 13, 2023)

View Bio X Cell's full profile

Bio X Cell is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BIO X CELL CIN: 43383727 , United States, Active	Dec 26, 999	-	23 (As on Dec 31, 2022)	-

Bio X Cell got acquired by Windjammer Capital Investors on Dec 13, 2023.

Click here to take a look at Bio X Cell's acquisition in detail

Bio X Cell has not raised any funding rounds yet.

The founders of Bio X Cell is Klaus Lubbe.

Here are the details of Bio X Cell's key team members:

Klaus Lubbe: Founder of Bio X Cell and founder of 1 other company.
Contact Info: 2 email addresses

View details of Bio X Cell's Founder profiles and Board Members

Bio X Cell's employee count trend

Bio X Cell has 23 employees as of Dec 22. The total employee count is 35.0% more than what it was in Dec 21. Here is Bio X Cell's employee count trend over the years:

Uncover Bio X Cell's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Bio X Cell include Sino Biological, GenScript and Y-Biologics. Here is the list of Top 10 competitors of Bio X Cell, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sino Biological 2007, Beijing (China), Series A	Provider of reagents,and kits for clinical research	$29.4M	CTS Capital, Qiming Venture Partners & 1 others	65/100
2nd	GenScript 2002, Piscataway (United States), Public	Provider of reagents and instruments for life sciences research	$15M	Kleiner Perkins, Vermögensclub & 1 others	59/100
3rd	Y-Biologics 2007, Daejeon (South Korea), Public	Developer of antibodies for the treatment of multiple diseases	$42.1M	InterVest, IMM Investment & 14 others	56/100
4th	Shanghai OPM Biosciences 2013, Pudong (China), Series B	Antibody culture media and vaccine culture products developer	$14.4M	CPE, China Life Great Health Fund & 5 others	54/100
5th	Allele Biotech 1999, San Diego (United States), Series B	cGMP iPSCs and cell therapy CDMO accelerating regenerative medicine programs	$18M	NIH, HHS & 1 others	52/100
6th	ITBMed 2016, Stockholm (Sweden), Series A	Developer of monoclonal antibodies to prevent transplant rejections	$87M	Yonjin Capital, 3E Bioventures Capital & 2 others	51/100
7th	Bio X Cell 1997, Lebanon (United States), Acquired	Provider of antibodies and antibody production services for in vivo use	-	-	50/100
8th	Mabtech 1986, Nacka (Sweden), Acquired	Develops antibodies and ELISA kits	-	Merieux Equity Partners, IK Partners & 1 others	50/100
9th	Pixelgen Technolgies 2020, Stockholm (Sweden), Series A	Developer of ground-breaking technologies for biomedical research and diagnostics	$6M	Industrifonden, Navigare Ventures & 1 others	50/100
10th	Immuno-Biological Laboratories 1982, Fujioka (Japan), Public	Manufacture antibodies	-	Japan Asia Investment, Hokkaido Venture Capital ... & 3 others	49/100